The Role of Memantine in the Treatment of Psychiatric Disorders Other Than the Dementias: A Review of Current Preclinical and Clinical Evidence
The DOI matches its Crossref record; 238 of the 238 references it cites were found in a registry or an index.
Abstract
Memantine, a non-competitive NMDA receptor antagonist approved for Alzheimer's disease with a good safety profile, is increasingly being studied in a variety of non-dementia psychiatric disorders. We aimed to critically review relevant literature on the use of the drug in such disorders. We performed a PubMed search of the effects of memantine in animal models of psychiatric disorders and its effects in human studies of specific psychiatric disorders. The bulk of the data relates to the effects of memantine in major depressive disorder and schizophrenia, although more recent studies have provided data on the use of the drug in bipolar disorder as an add-on. Despite interesting preclinical data, results in major depression are not encouraging. Animal studies investigating the possible usefulness of memantine in schizophrenia are controversial; however, interesting findings were obtained in open studies of schizophrenia, but negative placebo-controlled, double-blind studies cast doubt on their validity. The effects of memantine in anxiety disorders have been poorly investigated, but data indicate that the use of the drug in obsessive-compulsive disorder and post-traumatic stress disorder holds promise, while findings relating to generalized anxiety disorder are rather disappointing. Results in eating disorders, catatonia, impulse control disorders (pathological gambling), substance and alcohol abuse/dependence, and attention-deficit hyperactivity disorder are inconclusive. In most psychiatric non-Alzheimer's disease conditions, the clinical data fail to support the usefulness of memantine as monotherapy or add-on treatment However, recent preclinical and clinical findings suggest that add-on memantine may show antimanic and mood-stabilizing effects in treatment-resistant bipolar disorder.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, it also failed to affect emotional processing (facial emotion recognition and attentional vigilance to emotional words) and indeed potentiated the startle response (Sani et al. 2012, Pringle et al., 2012).”
From Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment (2021) · cites this paper as Sani et al. 2012
Citations
Cites
1 retracted
Items 201–238 of 238
Memantine in Major Depression with Catatonic Features
Muñoz, C., Yulan, N., Achaval, V., Appiani, F. J., & Carroll, B. T. (2008) · Journal of Neuropsychiatry · doi:10.1176/jnp.2008.20.1.119 · Cited by 28
Koronyo‐Hamaoui, M., Frisch, A., STEIN, D., DENZIGER, Y., Leor, S., Michaelovsky, E., Laufer, N., Carel, C. A., Fennig, S., Mimouni, M., et al. (2005) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2005.07.010 · Cited by 27
D’Aquila, P. S., Peana, A. T., Tanda, O., & Serra, G. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)00876-7 · Cited by 26
Self-citationCollins, E. D., Vosberg, S. K., Ward, A. S., Haney, M., & Foltin, R. W. (2007) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.15.3.228 · Cited by 26
Effect of Memantine on Cue-Induced Alcohol Craving in Recovering Alcohol-Dependent Patients
Krupitsky, E. M. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.164.3.519 · Cited by 25
Letter to the Editor: “Amantadine and Memantine in Catatonic Schizophrenia”
Carroll, B. T., Thomas, C., & Jayanti, K. (2006) · Annals of Clinical Psychiatry · doi:10.1080/10401230600614710 · Cited by 25
D’Aquila, P. S., Collu, M., Devoto, P., & Serra, G. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00189-8 · Cited by 25
Self-citationFornaro, M. (2011) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/187152411794961031 · Cited by 25
Krupitsky, E. M., Masalov, D. V., Burakov, A. M., Didenko, T., Romanova, T. N., Bespalov, A., Neznanova, O., Grinenko, N. I., Grinenko, A. Y., Slavina, T. Y., et al. (2002) · Addictive Disorders & Their Treatment · doi:10.1097/00132576-200211000-00006 · Cited by 23
The NMDA receptor antagonist MK-801 prevents imipramine-induced supersensitivity to quinpirole
D’Aquila, P. S., Sias, A., Gessa, G. L., & Serra, G. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90805-e · Cited by 23
Self-citationPharmacology of NMDA receptors
JANE, D. (2001) · CRC Press eBooks · doi:10.1201/9780203299388-7 · Cited by 23
Nussbaum, D. S., Honarmand, K., Govoni, R., Kalahani-Bargis, M., Bass, S. N., Ni, X., LaForge, K., Burden, A. M., Romero, K., Basarke, S., et al. (2010) · Journal of Gambling Studies · doi:10.1007/s10899-010-9219-8 · Cited by 23
Collins, E. D., Vosburg, S. K., Ward, A. S., Haney, M., & Foltin, R. W. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.12.003 · Cited by 23
Blevins, J. E., Truong, B. G., & Gietzen, D. W. (2004) · Brain Research · doi:10.1016/j.brainres.2004.05.089 · Cited by 22
Rasmussen, K., & Vandergriff, J. L. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(02)00296-4 · Cited by 22
Molander, L., & Randrup, A. A. (1976) · Psychopharmacology · doi:10.1007/bf00427282 · Cited by 22
Thuerauf, N., Lunkenheimer, J., Lunkenheimer, B., Sperling, W., Bleich, S., Schlabeck, M., Wiltfang, J., & Kornhuber, J. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0570-y · Cited by 20
Memantine normalizes brain activity in the inferior frontal gyrus: A controlled pilot fMRI study
Cerullo, M. A., Nasrallah, H. A., Eliassen, J. C., Adler, C. M., Nasrallah, A. T., & Strakowski, S. M. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.07.034 · Cited by 20
D’Aquila, P. S., Collu, M., Gessa, G. L., & Serra, G. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01019-4 · Cited by 19
Self-citationMuhonen, L. H., Lahti, J. M. T., Alho, H., Lönnqvist, J. K., Haukka, J. K., & Saarikoski, S. T. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2010.07.039 · Cited by 19
Memantine strikes the perfect balance
Spada, A. R. L. (2009) · Nature Medicine · doi:10.1038/nm1209-1355 · Cited by 19
[Antiepileptic drugs in the control of the impulses disorders].
Roncero, C., Rodríguez‐Urrutia, A., Grau‐López, L., & Casas, M. (2009) · Actas Españolas de Psiquiatría · Cited by 19
Marusich, J. A., McCuddy, W. T., Beckmann, J. S., Gipson, C. D., & Bardo, M. T. (2011) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32834d623e · Cited by 18
Dopaminergic ventral tegmental neurons modulated by methylphenidate
Prieto-Gómez, B., Benitez, M., Vázquez-Álvarez, A. M., Yang, P. B., Vazquez, C. R., & Dafny, N. (2003) · Life Sciences · doi:10.1016/j.lfs.2003.07.047 · Cited by 18
Wald, R., Dodman, N. H., & Shuster, L. (2009) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0016402 · Cited by 18
Long-term imipramine effects are prevented by NMDA receptor blockade
Montis, M. G. D., Gambarana, C., Meloni, D., Taddei, I., & Tagliamonte, A. (1993) · Brain Research · doi:10.1016/0006-8993(93)91570-i · Cited by 17
de Lucena, D. F., Fernandes, B. S., Kunz, M., Fries, G. R., Stertz, L., de Aguiar, B. W., Pfaffenseller, B., & Gama, C. S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09l05388 · Cited by 17
D’Aquila, P. S., Panin, F., & Serra, G. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.02.016 · Cited by 16
Self-citationSensitization to apomorphine, effects of dizocilpine NMDA receptor blockades
Acerbo, M. J., Lee, J. M., & Delius, J. D. (2003) · Behavioural Brain Research · doi:10.1016/j.bbr.2003.08.021 · Cited by 16
Memantine for Alcohol Dependence: An Open-label Pilot Study
Arias, A. J., Feinn, R., Covault, J., & Kranzler, H. R. (2007) · Addictive Disorders & Their Treatment · doi:10.1097/01.adt.0000210724.41187.4a · Cited by 14
Dubey, S. K., Patni, A. K., Khuroo, A. H., Thudi, N. R., Reyar, S., Kumar, A., Tomar, M. S., Jain, R. K., kumar, N. A., & Monif, T. (2009) · Journal of Chemistry · doi:10.1155/2009/748492 · Cited by 14
Jones, R. W. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2387 · Cited by 12
Memantine Dosing in Patients With Dementia
Dolder, C. R., Nelson, M., & McKinsey, J. (2009) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e318186bd7b · Cited by 11
Memantine for Posttraumatic Stress Disorder in an Older Veteran
Chopra, M. P., Trevino, K. M., & Kowall, N. W. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823657bf · Cited by 11
Pondé, M. P., & Novaes, C. M. (2007) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462007000100028 · Cited by 9
Memantine in Major Depression with Catatonic Features
Munoz, C., Yulan, N., Achaval, V., et al. (2008) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.20.1.119 · Cited by 9
Leon, A. C. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11lr07077a · Cited by 5
Improvement of Pathologic Gambling Symptoms After Administration of Sertraline: A Case Report
Meroni, M. C., Giudice, A. L., Kotzalidis, G. D., & Biondi, M. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000126666.83068.a9 · Cited by 4
Self-citation
Research works printed but not linked: 8
- Dingledine, 1999, Pharmacol Rev, 51, 7
- Danysz, 1995, Behav Pharmacol, 6, 455
- Petrović, 2005, Prague Med Rep, 106, 113
- Berger, 2003, Psychopharmacol Bull, 37, 79
- Feusner, 2009, Psychopharmacology Bull, 42, 81
- Roncero, 2009, Actas Esp Psiquiatr, 37, 205
- Grant, 2011, Erratum in: Br J Psychiatry, 198, 75
- Parsons, 2005, Handb Exp Pharmacol, &NA;, 249
Cited by
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
“Memantine, an NMDA receptor antagonist FDA-approved for the treatment of Alzheimer dementia, moderate-severe, was tested previously in preclinical studies as a potential antidepressant (168).”
BackgroundMemantine for Alzheimer’s Disease: An Updated Systematic Review and Meta-analysis
Kishi, T., Matsunaga, S., Oya, K., Nomura, I., Ikuta, T., & Iwata, N. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170424 · Cited by 249
Sanacora, G., & Schatzberg, A. F. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.261 · Cited by 160
Godlewska, B. R., & Harmer, C. J. (2021) · Psychopharmacology · doi:10.1007/s00213-019-05448-0 · Cited by 123
Recent insights into the mode of action of memantine and ketamine
Johnson, J. W., Glasgow, N. G., & Povysheva, N. V. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.11.006 · Cited by 116
Metadata
- Authors
- Sani, G., Serra, G., Kotzalidis, G. D., Romano, S., Tamorri, S. M., Manfredi, G., Caloro, M., Telesforo, C. L., Caltagirone, S. S., Panaccione, I., Simonetti, A., Demontis, F., Serra, G., & Girardi, P.
- Affiliations
- Azienda Ospedaliera Sant'Andrea (IT)
- University of Sassari (IT)
- Corresponding author
- Sani, Gabriele
- ORCID
- Venue
- CNS Drugs
- Published
- 2012-08
- Volume
- 26
- Issue
- 8
- Pages
- 663-690
- ISSN
- 1172-7047 (ISSN-L)
- OpenAlex
- W1524631360
- Cited by
- 273
- References
- 238
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 4 · 2023: 2 · 2022: 8 · 2021: 6 · 2020: 160 · 2019: 7 · 2018: 7 · 2017: 8 · 2016: 11 · 2015: 17 · 2014: 19 · 2013: 14
- FWCI
- 1.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- memantine, NMDA receptor antagonists, major depressive disorder, schizophrenia, bipolar disorder, obsessive-compulsive disorder, post-traumatic stress disorder, generalized anxiety disorder, eating disorders, catatonia, impulse control disorders, substance use disorders, alcoholism, attention deficit hyperactivity disorder, adjunctive therapy, treatment-resistant bipolar disorder, mood stabilization
- MeSH terms
- Animals, Mental Disorders, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Memantine, Treatment Outcome, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.